Integrated metabolomic and proteomic analyses reveal that coronary heart disease progression—from stable angina pectoris to acute myocardial infarction—features a dramatic escalation in molecular pathway crosstalk, culminating in a tightly coupled “molecular storm” characterized by heavily connected hubs such as L-glutamate and KNG1.
Stage-by-Stage Pathway Expansion in Coronary Heart Disease
The number of pathways co-enriched in both metabolomic and proteomic analyses increases markedly as clinical stages of coronary heart disease (CHD) advance. According to integrated omics cohort findings, researchers identified only two co-enriched pathways—histidine metabolism alongside arginine and proline metabolism—during the stable angina pectoris (SAP) stage. This baseline complexity shifts significantly when patients progress to unstable angina pectoris (UAP).
Data show that the UAP stage expands to five co-enriched pathways, incorporating critical cellular processes like ferroptosis and efferocytosis. By the time patients reach acute myocardial infarction (AMI), that number surges to 25 pathways. These encompass three major functional modules: immune inflammation, metabolic reprogramming, and cell signaling. This stepwise cascade maps out how biochemical networks tighten as arterial plaque vulnerability turns into acute ischemic events.
Did you know? The transition from stable angina to acute myocardial infarction involves a leap from just 2 identical metabolic pathways to 25 interconnected functional modules, highlighting a massive shift in systemic molecular signaling.
Core Network Connectivity and Central Molecular Hubs
Network connectivity exhibits a structural evolution as disease severity worsens. The core network shifts from a sparse architecture observed in SAP to a highly interconnected configuration in AMI. Within this cross-sectional network, L-glutamate and KNG1 emerge as the central hub molecules driving the systemic response.
Furthermore, specific proteins undergo distinct functional transitions across these stages. CNDP1 exhibits a stage-dependent shift, moving from downregulation during the SAP phase to marked upregulation in AMI. According to the cross-sectional analysis, metabolic dysregulation and immune activation display stepwise increases in interconnectivity, producing the extensive crosstalk that defines the AMI stage.
Therapeutic Implications for Stage-Oriented Interventions
Mapping these stage-associated molecular signatures offers a new framework for targeted drug development and diagnostic tracking. Traditional management often treats coronary heart disease through broad categories, but multi-omics data point toward stage-specific vulnerabilities. Pinpointing L-glutamate and KNG1 as central network hubs gives researchers concrete targets for stage-oriented therapeutic investigations.
Clinical approaches may eventually leverage these molecular transitions to intercept patients before they transition from unstable angina to myocardial infarction. By disrupting the early activation of pathways like ferroptosis during the UAP phase, clinicians might blunt the formation of the severe molecular storms typically witnessed in acute events.
Pro Tip: Researchers examining multi-omics data should focus on molecules demonstrating directional shifts—such as CNDP1 moving from downregulation to upregulation—as these indicate active remodeling during clinical progression.
Frequently Asked Questions
What are the main stages of coronary heart disease analyzed in multi-omics studies?
Studies typically evaluate stable angina pectoris (SAP), unstable angina pectoris (UAP), and acute myocardial infarction (AMI), alongside healthy control groups.
How many pathways are co-enriched in stable angina versus myocardial infarction?
Only 2 pathways are co-enriched in SAP, compared to 25 pathways encompassing immune inflammation, metabolic reprogramming, and cell signaling in AMI.
What are the central hub molecules identified in the AMI network?
L-glutamate and KNG1 are identified as the central hub molecules in the cross-sectional molecular network.
Want to stay updated on the latest breakthroughs in cardiovascular metabolomics and precision medicine? Subscribe to our weekly research briefing or leave a comment below to share your perspective on stage-specific therapeutic targets.
Related reading